Clinical Trials Logo

Neuroendocrine Tumours clinical trials

View clinical trials related to Neuroendocrine Tumours.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02788578 Terminated - Clinical trials for Neuroendocrine Tumours

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours

PRELUDE
Start date: June 2016
Phase:
Study type: Observational

The objective of the PRELUDE study is to describe the use of lanreotide Autogel® (LAN ATG) combined with Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of progressive neuroendocrine tumours located in the lung or in the digestive system as there is currently limited data on these treatments used together for these types of neuroendocrine tumours.

NCT ID: NCT00323076 Terminated - Clinical trials for Renal Cell Carcinoma

[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours

Start date: September 12, 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity. The presence of hypoxia (low oxygen) is associated with poor prognosis in a variety of tumour types and treatment strategies targeting hypoxic cells have been developed. The PET tracer [18]F-FAZA can identify hypoxic areas, and changes in uptake during treatment may predict tumour response.